BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Sabre//Sabre VObject 4.5.8//EN
CALSCALE:GREGORIAN
BEGIN:VTIMEZONE
TZID:Europe/Zurich
X-LIC-LOCATION:Europe/Zurich
TZURL:http://tzurl.org/zoneinfo/Europe/Zurich
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:19810329T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:19961027T030000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:news1707@biomedizin.unibas.ch
DTSTAMP;TZID=Europe/Zurich:20260416T182230
DTSTART;TZID=Europe/Zurich:20260417T110000
SUMMARY:Guest Speaker: Dirk Schnappinger - Professor at the Weill Cornell M
 edical College
DESCRIPTION:Dirk Schnappinger joined Weill Cornell Medical College in 2001\
 , where he currently holds the position of Professor in the Department of 
 Microbiology & Immunology. He received his Ph.D. from the Friedrich-Alexan
 der University of Erlangen-Nürnberg\, Germany\, in 1998 for work on the r
 epressor controlling tetracycline resistance in Gram negative bacteria. Af
 ter his graduate work Dr. Schnappinger began to study the human pathogen 
 Mycobacterium tuberculosis (Mtb)\, first at UC Berkeley\, in the lab of Dr
 . Lee Riley\, and then at Stanford under the guidance of Dr. Gary Schoolni
 k\, where he helped to adapt microarray-based RNA profiling to the analysi
 s of bacterial pathogens. \\r\\nHis current research aims to help develop
  new medicines for the treatment and prevention of Tuberculosis (TB)\, an 
 infectious disease that still claims over a million lives each year. This 
 work began with developing a regulatory system that allows to turn Mtb g
 enes on and off\, both in vitro and during infections. His lab now applies
  this and other genetic approaches to evaluate Mtb gene products as new 
 targets for TB drug development by documenting the impact of their genetic
  inactivation on growth and persistence of Mtb in vitro and in mice\, help
  elucidate the mechanisms by which small molecules inhibit the growth of 
 Mtb\, improve safety of the M. bovis BCG vaccine and develop a human cha
 llenge model for TB.
X-ALT-DESC:<p>Dirk Schnappinger joined Weill Cornell Medical College in 200
 1\, where he currently holds the position of Professor in the Department o
 f Microbiology &amp\; Immunology. He received his Ph.D. from the Friedrich
 -Alexander University of Erlangen-Nürnberg\, Germany\, in 1998 for work o
 n the repressor controlling tetracycline resistance in Gram negative bacte
 ria. After his graduate work Dr. Schnappinger began to study the human pat
 hogen&nbsp\;<i>Mycobacterium tuberculosis (Mtb)</i>\, first at UC Berkeley
 \, in the lab of Dr. Lee Riley\, and then at Stanford under the guidance o
 f Dr. Gary Schoolnik\, where he helped to adapt microarray-based RNA profi
 ling to the analysis of bacterial pathogens.&nbsp\;</p>\n<p>His current re
 search aims to help develop new medicines for the treatment and prevention
  of Tuberculosis (TB)\, an infectious disease that still claims over a mil
 lion lives each year. This work began with developing a regulatory system 
 that allows to turn&nbsp\;<i>Mtb</i>&nbsp\;genes on and off\, both in vitr
 o and during infections. His lab now applies this and other genetic approa
 ches to evaluate&nbsp\;<i>Mtb</i>&nbsp\;gene products as new targets for T
 B drug development by documenting the impact of their genetic inactivation
  on growth and persistence of Mtb in vitro and in mice\, help elucidate th
 e mechanisms by which small molecules inhibit the growth of&nbsp\;<i>Mtb</
 i>\, improve safety of the&nbsp\;<i>M. bovis</i>&nbsp\;BCG vaccine and dev
 elop a human challenge model for TB.</p>
DTEND;TZID=Europe/Zurich:20260417T120000
END:VEVENT
END:VCALENDAR